Venture-Backed Glaucoma Co. Seeks To Raise $86.3M In IPO
Inotek Pharmaceuticals Corp., a venture capital-backed biotechnology company developing a monotherapy eye drop to treat glaucoma, is looking to raise up to $86.3 million in an initial public offering to complete...To view the full article, register now.
Already a subscriber? Click here to view full article